Navigation Links
Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
Date:4/14/2011

WALTHAM, Mass., April 14, 2011 /PRNewswire/ -- Proteon Therapeutics, Inc. has initiated enrollment in a Phase 2 clinical study of its lead product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis. This study follows successful completion of a 66-patient, double-blind, placebo-controlled Phase 1/2 study of PRT-201 in AVF patients that completed enrollment in July 2010.

"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant medical challenges associated with vascular access in CKD patients, and we are very excited about the potential for PRT-201 to dramatically improve care for dialysis patients," said Timothy P. Noyes, President and CEO of Proteon.  

The results of this Phase 2 study will be provided to Novartis under an agreement entered into in 2009, whereby Novartis was granted an exclusive option to acquire Proteon following the completion of a Phase 2 clinical study of PRT-201. Including the initial acquisition payment plus potential regulatory milestone payments, the acquisition deal with Novartis could exceed $550 million.

About PRT-201

PRT-201 is an investigational recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) and arteriovenous graft (AVG) outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown in certain preclinical settings to reduce neointimal hyperplasia formation, and to cause dilation of segments of arteries and veins following topical intraoperative application. These effects may decrease the number of interventions necessary to maintain AVF and AVG patency. Improved patency may lead to fewer corrective surgical procedures, fewer hospitalizations, lower costs and less suffering for dialysis patients. The development program to investigate PRT-201 for
'/>"/>

SOURCE Proteon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
8. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
9. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
10. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
11. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... Research and Markets  has announced the addition ... Strategic Business Report" report to their offering. ... Fuel Cells (SOFCs) in US$ Thousands. The report provides separate ... Europe , Asia-Pacific , ... for the period 2012 through 2020. Market data and analytics ...
(Date:8/19/2014)... GLEN BURNIE, Md. , Aug. 19, 2014 /PRNewswire/ ... the clinical research industry, recently announced the formation of ... is pleased to announce the addition of Dr. ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 ... insight across a variety of therapeutic areas and set ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... YORK, Feb. 23 NeoStem, Inc. (NYSE Alternext ... processing and long-term storage of adult stem cells ... signed a license agreement to obtain the exclusive ... applications for cosmetic facial and body procedures and ...
... Pa. and SHANGHAI, Feb. 23 Frontage Laboratories ... bioanalytical, pre-clinical, clinical and drug development services to ... has expanded its research and development agreement with ... Beijing Pharmaceutical Group ("Beijing Pharma"), to accelerate Beijing ...
... (Amex: ETC ) ("ETC" or the "Company") ... equipped to satisfy the requirements of Electronic Medical Records ... University on January 8, 2009, then President-Elect Barack ... care while lowering its costs, we will make the ...
Cached Biology Technology:NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 2NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 2Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 4Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 2Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 3Environmental Tectonics Corporation's BioMedical Division's Hyperbaric Chambers Address U.S. President Obama's Initiative to Computerize Medical Records 4
(Date:8/20/2014)... -- The second annual Biometrics UnPlugged Executive Summit, set ... on September 15, 2014, will feature ... Strategy at Samsung, and Philippe de Raet, Vice President, ... year,s event is Mobility at the Crossroads of ... Mobility at the Crossroads of Commerce & Privacy ...
(Date:8/19/2014)... release is available in German . ... inherently intermittent energy sources. If a large amount of electricity ... future, excess energy will have to be stored during productive ... existing storage capacities are far from adequate for the purpose. ... One important focus lies on battery systems that used to ...
(Date:8/19/2014)... retail seafood counters in 10 different states show ... to unexpectedly high levels of mercury, a harmful ... fish of the same species, but from a ... according to new research by University of Hawai,i ... is essential to allow consumers to choose sustainable ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... Aug. 20, 2012 With concerns about the possible health ... Horizon disaster still fresh in mind, scientists today described ... up oil slicks and keeps oil from sticking to the ... dispersant is used in common food products like peanut butter, ...
... MDBX) ( www.medboxinc.com ) Medbox, Inc. released ... of over $820,000 for the three-month period ending June 30. ... the year, and receivables jumped to an impressive 1.1 million. ... services and the sales of their proprietary prescription medicine dispensing ...
... wasps ( Polistes dominula ) advertise the size of their ... in BioMed Central,s open access journal Frontiers in Zoology ... Aposematism is used by many different animals to warn ... form of distinctive colouration or patterns which predators quickly learn ...
Cached Biology News:New oil spill dispersant made from ingredients in peanut butter, chocolate, ice cream 2Medbox, Inc. Releases 2nd Quarter Financials 2
... unique combination of Coulter volume and ... and accurate cell counting. This flow ... UV, allowing flexible fluorochrome selection for ... only achievable with larger, more expensive ...
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
... Protein/antibody delivery using PULSin may be ... For example, unlike traditional transfection, with PULSin ... the level and time course of proteins ... may provide more information than traditional RNA ...
... is an innovative reagent for highly efficient ... of living cells. Unlike DNA transfection, with ... amount and timing of exogenous proteins in ... can now be studied. Real time ...
Biology Products: